Becquerel

Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

Retrieved on: 
Monday, November 27, 2023
University of Alabama, Molecular imaging, VMT, Hospital, SSTR2, Neoplasm, University college, Survival, University of Iowa, NGAL, Veterinary medicine, Biology, Lipocalin-2, RPDC, Nuclear Medicine and Biology, Becquerel, Nuclear medicine, University, Quality control, Medicine, Doctor of Philosophy, Therapy, TU Dresden, Korea Military Academy, Knowledge, Biomarker, Toxicity, CATX, Radiopharmaceutical, PB, European Journal, Journal, Institute of technology, Glomus tumor, Medical imaging

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline. The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals.

Key Points: 
  • SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline.
  • The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals.
  • “The results from these preclinical studies are compelling and continue to support our ongoing clinical efforts to advance our novel lead-based targeted alpha-particle therapies.
  • Author Affiliations: University of Alabama at Birmingham, Alabama, USA; Perspective Therapeutics, Coralville, Iowa, USA; The University of Iowa, Iowa City, Iowa, USA.

Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients

Retrieved on: 
Friday, October 27, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, International Congress on Tuberculosis, IND, Food, Progression-free survival, Cancer, Colorectal cancer, PFS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIPEC, Becquerel, Hyperthermic intraperitoneal chemotherapy, Safety, CRS, Patient, Pharmaceutical industry

“We are excited to announce the IND clearance for Radspherin® for colorectal cancer patients following the promising indications of safety and efficacy from the RAD-18-002 Phase 1/2a clinical trial,” said Anders Månsson, Chief Executive Officer of Oncoinvent.

Key Points: 
  • “We are excited to announce the IND clearance for Radspherin® for colorectal cancer patients following the promising indications of safety and efficacy from the RAD-18-002 Phase 1/2a clinical trial,” said Anders Månsson, Chief Executive Officer of Oncoinvent.
  • “This is an important corporate milestone for Oncoinvent, allowing us to clinically advance Radspherin® and expand to the U.S. landscape.
  • Oncoinvent recently presented preliminary 18-month safety and efficacy data from the ongoing RAD-18-002 study in patients with peritoneal carcinomatosis from colorectal cancer at the 13th International Congress on Peritoneal Surface Malignancies (PSOGI).
  • At 18 months, none of the 12 patients who received the recommended dose of 7 MBq experienced peritoneal recurrences.

Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies

Retrieved on: 
Wednesday, October 4, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Palazzo del Cinema di Venezia, Hyperthermic intraperitoneal chemotherapy, CET, Malignancy, Survival, EDT, Patient, Colorectal cancer, Becquerel, Recurrence, International Congress on Tuberculosis, Safety, Pharmaceutical industry

“We are thrilled to continue to demonstrate the robust safety and efficacy profile of Radspherin® with the presentation of 18-month data at PSOGI.

Key Points: 
  • “We are thrilled to continue to demonstrate the robust safety and efficacy profile of Radspherin® with the presentation of 18-month data at PSOGI.
  • At 18 months, none of the patients administered Radspherin® at the recommended dose experienced peritoneal recurrences.
  • “These data represent a significant clinical milestone for Radspherin®, giving us confidence in its potential to prevent peritoneal recurrence.
  • A total of 23 patients with peritoneal metastasis from colorectal cancer were enrolled, with 12 receiving the recommended dose of 7MBq.

Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)

Retrieved on: 
Thursday, September 28, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibroadenoma, European Society of Gynaecological Oncology, DLT, Congress Center, ESGO, University Clinical Centre in Gdańsk, Congress, Patient, Becquerel, Cytoreductive surgery, Istanbul Congress Center, Ovarian cancer, Safety, Pharmaceutical industry

"Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.

Key Points: 
  • "Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.
  • We believe this is an important first step as we advance the development of Radspherin® as a new treatment for patients with advanced ovarian cancer,” says CEO Anders Månsson.
  • The safety interim analysis after completion of the dose-limiting toxicity (DLT) period demonstrated that Radspherin® was well tolerated.
  • The highest dose of 7 MBq was recommended following the completion of dose escalation of 1-2-4-7 MBq, as no DLT was observed.

Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Radium, McCormick Place, CRS, Survival, Prognosis, Peritoneum, ASCO, American Society of Clinical Oncology, Patient, Data, Colorectal cancer, Annual general meeting, Becquerel, Oslo University Hospital, Radiumhospitalet, Poster, Ovarian cancer, Recurrence, Society, Safety, Pharmaceutical industry

The poster, titled “15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer” will be presented by Dr Stein Larsen from the Norwegian Radium Hospital during the “Gastrointestinal Cancer – Colorectal and Anal” session from 8:00 a.m. to 11:00 a.m.

Key Points: 
  • The poster, titled “15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer” will be presented by Dr Stein Larsen from the Norwegian Radium Hospital during the “Gastrointestinal Cancer – Colorectal and Anal” session from 8:00 a.m. to 11:00 a.m.
  • There will additionally be a poster discussion session from 1:15 p.m. to 2:45 p.m. on June 5, 2023.
  • ET
    This Phase 1/2A study is designed to evaluate the safety, tolerability, and signal of efficacy of Radspherin® injected intraperitoneally two days after the completion of CRS-HIPEC.
  • Assessment of safety and efficacy was performed every three months; this dataset includes safety and survival data at the 15-month mark.

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

Retrieved on: 
Monday, May 16, 2022
Cancer, Becquerel, Risk, CEO, MTD, Gallium, Radiation, Annual general meeting, Private Securities Litigation Reform Act, Letter, Abstract, Patient, Poster, NASDAQ, AACR, HEK, MCRPC, Clinical trial, Association, COVID-19, Radioligand, Intention, Dosimetry, FAP, Index (publishing), American Association for Cancer Research, Prostate cancer, Program, Terminology, Forward-looking statement, Tolerability, Heterotrimeric G protein, SPLASH, Therapy, Health Canada, Safety, American Association, Isotope, Radiopharmaceutical, SEC, Prevalence, GLOBE, Actinium-225, Melanoma, Molecular imaging, Medical imaging, Pharmaceutical industry

INDIANAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced details of the initial clinical trial in the Company’s pan-cancer Fibroblast Activation Protein-α (FAP-α) targeted program PNT2004, FRONTIER.

Key Points: 
  • The Phase 1 clinical protocol will evaluate PNT6555 in ~30 patients in five FAP-avid cancer indications: colorectal, pancreatic, esophageal, melanoma, and soft tissue sarcoma.
  • We believe radiopharmaceuticals are on the verge of a revolution, said Dr. Joe McCann, CEO of POINT Biopharma.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .

Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Wednesday, October 20, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Transfer, Safety, Ovarian cancer, Neutrophil, Depression, Radiation, Cell proliferation, Calcium carbonate, Association, Neoplasm, Survival, Colorectal cancer, Radionuclide, Human, Carboplatin, Alpha, LET, CI, Patient, Mouse, EANM, RBE, Becquerel, Linear energy transfer, Nuclear medicine, Cell, Ascites, Growth, Tissue, Peritoneal cavity, European Association of Urology, Half-life, PARP, PLD, Medical imaging, Platinum, Birth control, Pharmaceutical industry, Lithium

We look forward to the continued clinical development of Radspherin in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.

Key Points: 
  • We look forward to the continued clinical development of Radspherin in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.
  • Ovarian cancer mouse models were treated with 224Ra-CaCO3-MP (5 mg, 14-22 kBq/animal) one day following tumor cell inoculation.
  • When 224Ra-CaCO3-MP was administered in combination with carboplatin-PLD, survival was significantly prolonged compared to mice that received carboplatin-PLD alone.
  • Radspherin is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.